Yuan Zhao

Dr. Yuan Zhao


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2014 in Journal of Lipid Research
Verified
Journal Article
Open access
PDF file
XTXiaoyun Tang
Xiaoyun Tang
Matthew G.K. BeneschMatthew G.K. Benesch
Matthew G.K. Benesch
JDJay Dewald
Jay Dewald
YZYuan Zhao
Yuan Zhao
NPNeeraj Patwardhan
Neeraj Patwardhan
David N. BrindleyDavid N. Brindley
David N. Brindley
Lipid phosphate phosphatase-1 (LPP1) degrades lysophosphatidate (LPA) and attenuates receptor-mediated signaling. LPP1 expression is low in many cancer cells and tumors compared with normal tissues. It was hypothesized from studies with cultured cells that increasing LPP1 activity would decrease tumor growth and metastasis. This hypothesis has never been tested in vivo. To do this, we inducibly expressed LPP1 or a catalytically inactive mutant in cancer cells. Expressing active LPP1 increased extracellular LPA degradation by 5-fold. It also decreased the stimulation of Ca2+ transients by LPA, a nondephosphorylatable LPA1/2 receptor agonist and a protease-activated receptor-1 peptide. The latter results demonstrate that LPP1 has effects downstream of receptor activation. Decreased Ca2+ mobilization and Rho activation contributed to the effects of LPP1 in attenuating the LPA-induced migration of MDA-MB-231 breast cancer cells and their growth in 3D culture. Increasing LPP1 expression in breast and thyroid cancer cells decreased tumor growth and the metastasis by up to 80% compared with expression of inactive LPP1 or green fluorescent protein in syngeneic and xenograft mouse models. The present work demonstrates for the first time that increasing the LPP1 activity in three lines of aggressive cancer cells decreases their abilities to produce tumors and metastases in mice.

10 February 2019 in Disease Markers
Verified
Journal Article
Open access
PDF file
LYLong Yao
Long Yao
MLMengke Liu
Mengke Liu
YHYunlong Huang
Yunlong Huang
KWKaiming Wu
Kaiming Wu
XHXin Huang
Xin Huang
RZRenquan Zhang
Renquan Zhang
Background. Antidiabetic medications (ADMs) can alter the risk of different types of cancer, but the relationship between lung cancer incidence and metformin remains controversial. Our aim was to quantitatively estimate the relationship between incidences of lung cancer and metformin in patients with diabetes in this meta-analysis. Methods. We performed a search in PubMed, Embase, ISI Web of Science, and Cochrane Library until September 20, 2017. The odds ratio (OR), relative risk (RR) or hazard ratio (HR), and 95% confidence interval (95% CI) were estimated using the random-effect model. The Newcastle-Ottawa Scale (NOS) was used to assess the study quality. Results. A total of 13 studies (10 cohort studies and 3 case-control studies) were included in the meta-analysis. Compared to nonmetformin users, metformin probably decreased lung cancer incidence in diabetic patients (RR=0.89; 95% CI, 0.83-0.96; P=0.002) with significant heterogeneity (Q=35.47, I2=66%, P=0.0004). Subgroup analysis showed that cohort studies (RR=0.91; 95% CI, 0.85-0.98; P=0.008), location in Europe (RR=0.90; 95% CI, 0.86-0.94; P<0.0001), the control drug of the sulfonylurea group (RR=0.91; 95% CI, 0.86-0.96; P=0.001), and adjusting for smoking (RR=0.86; 95% CI, 0.75-1.00; P=0.05) may be related to lower lung cancer risk. No significant publication bias was detected using a funnel plot. Conclusion. Metformin use was related to a lower lung cancer risk in diabetic patients compared to nonusers, but this result was retrieved from observational studies and our findings need more well-designed RCTs to confirm the association.


3 August 2025 in The American Surgeon™
Verified
Journal Article
Closed access
YZYuan Zhao
Yuan Zhao
FYFei Yuan
Fei Yuan
WLWen Liu
Wen Liu
JZJianhui Zuo
Jianhui Zuo
RZRenquan Zhang
Renquan Zhang
Objective: As pulmonary segmentectomy becomes increasingly common in the treatment of early-stage lung cancer, providing relevant clinical training for residents is essential. However, understanding pulmonary segment anatomy can be challenging due to its complex and variable structures. This study aimed to evaluate the value of automated three-dimensional CT bronchography and angiography (3D-CTBA) technology in training surgical residents for segmentectomy. Methods: Fifty-two surgical residents were randomized into 2 groups: the 3D-CTBA group and the control group. The 3D-CTBA group utilized automated 3D-CTBA technology alongside specific case for segmentectomy training, while the control group relied on traditional teaching methods. After the training sessions, all participants completed a post-training assessment and questionnaires. Additionally, we collected feedback from instructors regarding the residents’ performance through a separate questionnaire. Results: Residents in the 3D-CTBA group achieved significantly higher scores on the post-training assessments than those in the control group (83.46 ± 6.75 vs 68.27 ± 8.12, P < 0.001). Subjective survey results indicated that automated 3D-CTBA technology greatly benefited residents in preoperatively identifying tumor locations, recognizing anatomical variations during surgery, and mastering relevant surgical techniques. Feedback from instructors indicated that residents in the 3D-CTBA group performed better intraoperatively than those in the control group. Furthermore, residents in the 3D-CTBA group expressed greater interest in learning and higher satisfaction with the course. Conclusions: Automated 3D-CTBA technology significantly improved residents’ comprehension of the complex and variable anatomy of pulmonary segments, thereby enhancing their related surgical skills.